Eg Pharma Profile
Key Indicators
- Authorised Capital ₹ 2.40 M
- Paid Up Capital ₹ 2.19 M
- Company Age 23 Year, 4 Days
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 6.05 M
- Revenue Growth -81.51%
- Profit Growth -30.00%
- Ebitda
- Net Worth -0.41%
- Total Assets 0.14%
About Eg Pharma
Eg Pharma Private Limited (EPPL) is a Private Limited Indian Non-Government Company incorporated in India on 29 January 2002 and has a history of 23 years. Its registered office is in Punjab, Punjab.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.40 M and a paid-up capital of Rs 2.19 M.
The company currently has active open charges totaling ₹6.05 M.
Pankaj Gupta, Lokesh Sharma, and Santosh Sharma serve as directors at the Company.
Company Details
-
LocationPunjab, Punjab
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24232PB2002PTC024924
-
Company No.
024924
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
29 Jan 2002
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Chandigarh
Industry
Who are the key members and board of directors at Eg Pharma?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pankaj Gupta
|
Director | 29-Jan-2002 | Current |
|
Lokesh Sharma
|
Director | 29-Jan-2002 | Current |
|
Santosh Sharma
|
Director | 29-Jan-2002 | Current |
Financial Performance of Eg Pharma.
Eg Pharma Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 81.51% decrease. The company also saw a substantial fall in profitability, with a 30% decrease in profit. The company's net worth dipped by a decrease of 0.41%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Eg Pharma?
In 2023, Eg Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Levant Importers Private LimitedLokesh Sharma and Santosh Sharma are mutual person
-
Greenlab Initiative Private Limited
Lokesh Sharma is a mutual person
Charges (Loans)
₹6.05 M
₹0
Charges Breakdown by Lending Institutions
- Punjab National Bank : 0.48 Cr
- Bharat Overseas Bank : 0.13 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 12 Jun 2007 | Punjab National Bank | ₹4.80 M | Open |
| 24 Apr 2006 | Bharat Overseas Bank | ₹1.25 M | Open |
How Many Employees Work at Eg Pharma?
Unlock and access historical data on people associated with Eg Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Eg Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Eg Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
